Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model

DOI: 10.1128/AAC.01989-18

Article Information

DOI

PubMed

Published By

History

^aInstitute of Antibiotics, Fudan University & Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
^bCollege of Life Sciences, Shanghai Normal University, Shanghai, China
^cPhase I Unit, Huashan Hospital, Fudan University, Shanghai, China
^dShanghai Jiaotong University, Shanghai, China
^eBiomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Melbourne, Australia

Address correspondence to Jing Zhang, zhangj_fudan{at}aliyun.com.
X.B. and X.L. contributed equally to the manuscript.
Citation Bian X, Liu X, Chen Y, Chen D, Li J, Zhang J. 2019. Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 63:e01989-18. https://doi.org/10.1128/AAC.01989-18.

Rendering graph...